

Investment Objective

The Leverage Shares 3x Long Hims & Hers Health (HIMS) ETP Securities seeks to track the Euronext 3x Long Hims & Hers Health Index, which is designed to provide 3x the daily return of Hims & Hers Health, Inc. stock, adjusted to reflect the fees and costs of maintaining a leveraged position in the stock. It invests directly in the underlying Hims & Hers Health, Inc. stock and uses margin (borrowing) to purchase additional shares of Hims & Hers Health, Inc. stock.

For example, if Hims & Hers Health, Inc. rises by 1% over a day, then the ETP will rise by 3%, excluding fees. However, if Hims & Hers Health, Inc. falls by 1% over a day, then the ETP will fall by 3%, excluding fees.

Key Features

- Opportunity to magnify returns in one simple trade.
- Liquid. Trades like an equity on exchange, with multiple market makers.
- You cannot lose more than the amount you invest.
- An intraday rebalance mechanism (“airbag”) is designed to cushion the largest intra-day falls.
- Simple to trade, no need for futures or margin accounts.
- Transparent structure with full ownership of the underlying assets, so credit risk minimised.
- Independent structure managed by industry experts.

Key Risks

- Investing in Short and Leveraged ETPs is only suitable for sophisticated traders who understand leverage, daily rebalancing and compounded daily returns.
- Investors can lose the full value of their initial investment (but not more).
- Losses are magnified due to the nature of leveraged returns. Therefore, Short and Leveraged ETPs are only suitable for investors willing to take a high level of risk.
- Daily compounding may result in returns which an investor may not expect if the investor has not fully understood how a Leverage Shares ETP works.
- Due to daily rebalancing and compounding, ETP returns measured over periods longer than one day may differ from the returns of the underlying stock multiplied by the leverage factor.
- Only use these ETPs if you can monitor your positions daily.
- Please see the 'Risks Factors' section of the Prospectus for a more detailed discussion of the potential risks associated with an investment in this product.

Product Information

Product Name	Leverage Shares 3x Long Hims & Hers Health (HIMS) ETP Securities
Underlying Security	Hims & Hers Health, Inc.
Index / Strategy Tracked	Euronext 3x Long Hims & Hers Health Index
Leverage Factor	3
Replication	Physical
Base Currency	USD
ISIN	XS3304270351
Structure / Legal Form	ETP / Debt Security
Countries Available	United Kingdom, Italy, Germany, France, Spain, Netherlands, Ireland, Poland, Belgium, Sweden, Norway, Austria
Issuer	Leverage Shares PLC
Trustee	Apex Corporate Trustees (UK) Ltd
Margin Provider / Stock Lender	Interactive Brokers LLC and/or Morgan Stanley & Co. LLC
Margin Rate / Interest on Cash Balances	Fed Funds Effective (Overnight Rate) +2%
Stock Borrow Rate	N/A
Annual Management Fee	0.75%
SIPP/ISA Eligible	Yes
Sec871(m)	Not Applicable (see FAQs)

Index Information

Index	Euronext 3x Long Hims & Hers Health Index
Index Provider	Euronext
Index Currency	USD
Index Ticker	E3XLH

**Investors should refer to the Prospectus (www.leverageshares.com) for a more complete description of the product, service providers and relevant regulatory factors.*

Country	Exchange	Base Currency	Trading Currency	Exchange Code	ISIN	SEDOL	BBG Ticker	RIC	WKN	Listing Date
UK	London Stock Exchange	USD	USD	Produc	XS3304270351	BV89Q63	Produc LN	Prod.L	-	16/09/2025
UK	London Stock Exchange	USD	GBP	3HIM	XS3304270351	BV89Q74	3HIM LN	3HIM.L	-	16/09/2025
Italy	Borsa Italiana	USD	EUR	HIM3	XS3304270351	BV89Q85	HIM3 IM	HIM3.MI	-	22/10/2025

Contact Information

Contact us via email at info@leverageshares.com or on Twitter at [@LeverageShares](https://twitter.com/LeverageShares). More information on Leverage Shares can be found online at www.leverageshares.com.

Disclaimer

Leverage Shares ETPs are only intended for sophisticated traders who understand the associated risks and are able to monitor their positions on an intraday basis. Please consult an investment adviser to determine whether or not the products are suitable for you. Traders should also review the Relevant Prospectus (as defined below) and the Leverage Shares educational materials carefully before considering the ETPs.

No investment advice

Leverage Shares PLC is required by the FCA to clarify that it is not acting for you in any way in relation to the investment or investment activity to which this financial promotion relates. In particular, LEVERAGE SHARES PLC will not provide any investment services to you and/or advise you on the merits of, or make any recommendation to you in relation to, the terms of any transaction. No representative of LEVERAGE SHARES PLC is authorised to behave in any way which would lead you to believe otherwise. LEVERAGE SHARES PLC is not, therefore, responsible for providing you with the protections afforded to its clients and you should seek your own independent legal, investment and tax or other advice as you see fit.

No offer for sale

The information contained in this financial promotion is neither an offer for sale nor a solicitation of an offer to buy securities. This financial promotion should not be used as the basis for any investment decision.

Risk Warnings

The value of an investment in ETPs may go down as well as up and past performance is not a reliable indicator of future performance. An investment in ETPs is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely. ETPs offering daily leveraged or daily short exposures ("Leveraged ETPs") are products which feature specific risks that prospective investors should understand before investing in them.

Securities issued by the Issuer are products involving a significant degree of risk and may not be suitable for all types of investor. Any decision to invest should be based on the information contained in the Relevant Prospectus of the Issuer (or any supplements thereto) which includes, inter alia, information on certain risks associated with an investment. The price of any securities may go up or down and an investor may not get back the amount invested. Securities are priced in US Dollars/Euros/Pounds and the value of the investment in other currencies will be affected by exchange rate movements.

Short and leveraged exchange-traded products are only intended for investors who understand the risks involved in investing in a product with short and/or leveraged exposure and who intend to invest on a short-term basis. Any investment in short and/or leveraged products should be monitored on a daily basis to ensure consistency with your investment strategy. You should understand that investments in short and/or leveraged exchange-traded products held for a period of longer than one day may not provide returns equivalent to the return from the relevant unleveraged investment multiplied by the relevant leverage factor.

Potential losses in short and/or leveraged exchange-traded products may be magnified in comparison to investments that do not incorporate these strategies. Please refer to the section entitled "Risk Factors" in the relevant prospectus for further details of these and other risks associated with an investment in short and/or leveraged exchange traded products. You should consult an independent investment adviser prior to making an investment in short and/or leveraged exchange-traded products in order to determine its suitability to your circumstances.

Prospectus

A base prospectus has been approved by the Central Bank of Ireland as competent authority under Regulation (EU) 2017/1129 with respect to the offer and listing of ETPs in Ireland and certain other EU jurisdictions listed below (the "EU Prospectus"). A base prospectus has been approved by the Financial Conduct Authority as competent authority under the United Kingdom's version of Regulation (EU) No 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 with respect to the offer and listing of ETPs in the United Kingdom (the "UK Prospectus"). The "Relevant Prospectus" means the EU Prospectus or the UK Prospectus, as applicable.

The Central Bank of Ireland has delivered to the regulators listed below certificates of approval attesting that the EU Prospectus has been drawn up in accordance with Article 25 of Regulation (EU) 2017/1129.

The EU Prospectus (and any supplements thereto) of the Issuer has been passported from Ireland into Italy (Commissione Nazionale per la Società e la Borsa), Germany (Bundesanstalt für Finanzdienstleistungsaufsicht), France (Autorité des Marchés Financiers), Spain (Comisión Nacional del Mercado de Valores), the Netherlands (the Autoriteit Financiële Markten), Poland (Komisja Nadzoru Finansowego), Belgium (Belgian Financial Services and Markets Authority) and Austria (Finanzmarktaufsichtsbehörde).

Investors should read the Relevant Prospectus of the Issuer before investing and should refer to the section of the Relevant Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in this product.